Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 8,174 matching trials from the live ClinicalTrials.gov search.
Active, not recruiting No phase listed Observational

remedē System Therapy Study

NCT03884660
Conditions
Central Sleep Apnea
Interventions
remede System
Device
Lead sponsor
Respicardia, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
29
States / cities
Phoenix, Arizona • Scottsdale, Arizona • San Francisco, California + 24 more
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo matching Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 89 Years
Enrollment
2,245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 117 more
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
MN-221 (Dose Group 1), MN-221 (Dose Group 2), MN-221 (Dose Group 3)
Drug
Lead sponsor
MediciNova
Industry
Eligibility
40 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Fullerton, California • Tamarac, Florida + 4 more
Conditions
Lymphedema, Stage IA Cervical Cancer, Stage IA Uterine Corpus Cancer, Stage IA Vulvar Cancer, Stage IB Cervical Cancer, Stage IB Uterine Corpus Cancer, Stage IB Vulvar Cancer, Stage II Uterine Corpus Cancer, Stage II Vulvar Cancer, Stage IIA Cervical Cancer, Stage IIIA Vulvar Cancer, Stage IIIB Vulvar Cancer, Stage IIIC Vulvar Cancer, Stage IVB Vulvar Cancer
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Study of High Risk Factors, Therapeutic Conventional Surgery, Therapeutic Laparoscopic Surgery, Therapeutic Lymphadenectomy
Other · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
1,055 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
213
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 160 more
Conditions
Recurrent or Refractory Pediatric Ependymoma
Interventions
erlotinib, etoposide
Drug
Lead sponsor
OSI Pharmaceuticals
Industry
Eligibility
1 Year to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 14 more
Conditions
Amenorrhea
Interventions
DR-2021a, DR-2021b, DR-2021c, DR-2021d, DR-2021e, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
27
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 22 more
Conditions
Coronary Artery Disease (CAD), Coronary Atherosclerosis
Interventions
Placebo, Aliskiren
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
54
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 48 more
Conditions
Pain, Chronic Pain, Breakthrough Pain
Interventions
Fentanyl Buccal Tablets
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 29 more
Conditions
Pericarditis, Pericarditis Acute, Recurrent Pericarditis
Interventions
KPL-387, Placebo
Drug
Lead sponsor
Kiniksa Pharmaceuticals International, plc
Industry
Eligibility
18 Years to 80 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
33
States / cities
Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 27 more
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
Not listed
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
1,504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
192
States / cities
Huntsville, Alabama • Muscle Shoals, Alabama • Glendale, Arizona + 162 more
Conditions
Neovascular Age-related Macular Degeneration
Interventions
CLS-AX
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Mountain View, California • Sacramento, California + 4 more
Conditions
Emergencies
Interventions
Nurse-initiated triage, Self-triage kiosk
Other
Lead sponsor
Valleywise Health
Other
Eligibility
Up to 18 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Carcinoma of Unknown Primary
Interventions
radiation therapy
Radiation
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
237
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 180 more
Conditions
Dyslipidemia
Interventions
Evolocumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
40 Years to 85 Years
Enrollment
5,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
144
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 136 more
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Fruit and Vegetable Study - Pilot

NCT07727746
Conditions
Fruit and Vegetable Consumption in Children, Fruit and Vegetable Consumption, Fruit and Vegetable Selection in the Lunchroom, Caregiver Nutrition
Interventions
FFVP+, FFVP-only
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
7 Years to 65 Years
Enrollment
880 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Aripiprazole
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
26
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Conditions
Opioid-Induced Constipation (OIC)
Interventions
NKTR-118, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 84 Years
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
91
States / cities
Birmingham, Alabama • Calera, Alabama • Glendale, Arizona + 88 more
Conditions
Graft Occlusion, Vascular, Coronary Restenosis, Atherosclerosis
Interventions
BO-653
Drug
Lead sponsor
Chugai Pharma USA
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
29
States / cities
Phoenix, Arizona • Tucson, Arizona • Burlingame, California + 24 more
Completed Phase 2 Interventional Results available

Evaluating Neuroprotection in Aneurysm Coiling Therapy

NCT00728182
Conditions
Stroke
Interventions
NA-1, Placebo
Drug
Lead sponsor
NoNO Inc.
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Phoenix, Arizona • Stanford, California • Portland, Oregon
Conditions
Refractory or Unexplained Chronic Cough
Interventions
NOC-110, Placebo
Drug · Other
Lead sponsor
Nocion Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
68
States / cities
Foley, Alabama • Scottsdale, Arizona • Tempe, Arizona + 60 more
Conditions
Early-stage Parkinson's Disease
Interventions
UCB0599, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
40 Years to 75 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Conditions
Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Radiation Therapy, Sigmoidoscopy, Total Mesorectal Excision
Procedure · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
213
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 145 more
Conditions
Non-infectious Anterior Uveitis
Interventions
Tacrolimus ophthalmic solution
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
6
States / cities
Phoenix, Arizona • Miami, Florida • Waltham, Massachusetts + 3 more
Conditions
Stage III Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage IVA Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma, Stage IIC Adult Soft Tissue Sarcoma
Interventions
doxorubicin, filgrastim, ifosfamide, biological response modifier therapy, brachytherapy, chemotherapy, colony-stimulating factor therapy, conventional surgery, cytokine therapy, intraoperative radiotherapy, radiation therapy, surgery
Drug · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
216
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more